Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a new injection replace bone cement for spine fractures?

NCT ID NCT04835428

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new device (AGN1 LOEP) to standard bone cement for treating painful spine fractures caused by osteoporosis. The new device is injected into the broken vertebra, where it hardens and then slowly gets replaced by new bone. The trial involves 408 adults aged 50 and older with recent fractures. The goal is to see if the new device works as well as cement for pain relief and function, while also promoting bone regrowth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AGN1 LOEP SV Kit (a device that is injected into the fractured vertebra, resorbed, and replaced by new bone)
What this could lead to
If it works, this could offer a treatment for painful spine fractures that helps the body regrow bone rather than just filling the crack with cement.
What could go wrong
This is an early-stage non-inferiority trial, so the new device may not be as effective as standard cement. Risks include device-related complications or the need for further surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 408 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is a male or female 50 years of age or older at the time of study treatment. 2. Subject has one (1) or two (2) acute VCF(s). Note that subjects are eligible if they have an asymptomatic, healed VCF(s) at any non-target vertebral level. 3. Each target VCF meets all of the following criteria: 1. Due to diagnosed or presumed underlying osteoporosis 2. T1 to L5 inclusively 3. Target VCF-related pain ≤ 6 months at time of study treatment 4. Each target VCF shows loss of height of the vertebral body ≤ 50% based on X-ray at baseline. 5. Each target VCF is acute or persistent (not healed), as demonstrated on imaging, including T2-weighted, STIR MRI, bone scan or bone scan with SPECT/CT, serial radiographs, or other serial imaging demonstrating acuity. 6. Focal tenderness to palpation of the spinal process of each target VCF on the physical exam correlates with imaging. 7. Subject has failed conservative medical therapy (bed rest, observation, chiropractic care, orthotics, opioid and non-opioid analgesics, and/or physical therapy), defined as either having a VAS back pain score of ≥ 70 mm after 24 hours to 6 weeks of conservative care or a VAS back pain score of ≥ 50 mm after more than 6 weeks of conservative care. 8. Subject has an Oswestry Disability Index (ODI) score of ≥ 30% at baseline. 9. Subject is capable of giving written informed consent to participate in the study. 10. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full length of the study has been documented Exclusion Criteria: 1. At least one of the target VCF(s) is unstable, including split or burst fracture. 2. Subject has a bleeding disorder. 3. Subject has an active infection of the spine or surgical site. 4. Subject has a bloodborne infection. 5. At least one of the target VCFs is due to underlying or suspected tumor. 6. At least one of the target VCFs is due to high-energy trauma. 7. At least one of the target VCFs is due to osteonecrosis. 8. At least one of the target VCFs has a local kyphotic angle of \> 30 degrees, measured as the angle between the superior endplate and inferior endplate at the target VCF. 9. Subject has had any prior surgical treatment at the target vertebral level or adjacent vertebral levels. 10. The pedicle(s) in the target vertebral body appears unable to safely accommodate transpedicular access instrumentation. 11. Subject has neurologic symptoms, deficits, or radiculopathy related to the target VCF(s). 12. Subject has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated. 13. Subject has pain, progressive weakness, or paralysis due to herniated nucleus pulposus or spinal stenosis. 14. Subject has spondylolisthesis \> Grade 1 at target vertebral body(ies). 15. Subject requires daily opioid medication for pain not related to the target VCF(s). 16. Subject has severe cardiopulmonary deficiencies. 17. Subject has a Body Mass Index (BMI) \> 35. 18. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia). 19. Subject has a history of tuberculous spondylitis. 20. Subject has a history of invasive malignancy within the last five (5) years, other than non-melanoma skin cancer. Subject is not excluded if they have a history of malignancy over 5 years ago treated with curative intent and without clinical signs or symptoms since then. 21. Subject is on oral or parenteral immune-suppressive drugs. 22. Subject has uncontrolled diabetes mellitus. 23. Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 30 mL/min. 24. Subject has a diagnosed calcium metabolism disorder. 25. Subject has known allergies to calcium-based bone void fillers. 26. Subject is pregnant or planning to become pregnant during participation in the study. 27. In the judgment of the Investigator, the subject is not a good study candidate. (e.g. substance abuse or chemical dependency, inability to adhere to follow-up schedule, progression of the fracture between screening and the procedure visit). 28. Subject is currently enrolled in another interventional clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Compression fracture are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fractures, Compression spinal fracture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alabama Clinical Therapeutics

    Birmingham, Alabama, 35235, United States

  • Cleveland Clinic Florida

    Stuart, Florida, 34994, United States

  • Elite Pain and Spine Institute

    Mesa, Arizona, 85203, United States

  • Endeavor Health

    Evanston, Illinois, 60201, United States

  • Lahey Medical Center

    Burlington, Massachusetts, 01805, United States

  • Louisiana Spine Institute

    Shreveport, Louisiana, 71101, United States

  • Montefiore

    The Bronx, New York, 10467, United States

  • Orlando Neurosurgery (Conquest Research)

    Orlando, Florida, 32804, United States

  • Pinehurst Surgical Clinic

    Pinehurst, North Carolina, 28374, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • Texas Back Institute

    Plano, Texas, 75093, United States

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.